Mode
Text Size
Log in / Sign up
N/A N=15 Basic Science

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

Cystic Fibrosis

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Nrf2 Activation in Nasal Epithelial Cells — 0; 0; 4; 4 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Broccoli sprouts (Dietary_supplement)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University Hospitals Cleveland Medical Center
Primary completion
Feb 2013

Outcome Measures

OutcomeResultp-value
PRIMARY
Nrf2 Activation in Nasal Epithelial Cells
0; 0; 4; 4
SECONDARY
Measures of Lipid Peroxidation in Nasal Epithelial Cells
SECONDARY
Measures of Glutathione From Blood Lymphocytes
14.3; 4.7
SECONDARY
Measures of Oxidative Stress in Urine
0.09; 0.01
SECONDARY
Measure of Neutrophil Migration Into the Gingival Crevices
-0.06; -0.02

Summary

The purpose of this study to investigate the effect of sulforaphane from macerated broccoli sprouts in humans and to evaluate less invasive methods of assessing potential anti-inflammatory drugs in CF.

Eligibility Criteria

Inclusion Criteria

  • Healthy volunteers and patients with cystic fibrosis ≥ 18 50% (in the last year, obtained from medical record)
  • CF subjects must be clinically stable: free of any acute illness for > 14 days CF subjects must not have been prescribed any new systemic antibiotics for the 14 days prior to enrollment
  • Ability to provide written informed consent
  • Ability to adhere to the protocol

Exclusion Criteria

  • Use of NSAIDS (e.g., ibuprofen) or corticosteroids including inhaled steroids for the 4 weeks prior to enrollment
  • Active gingival disease (active tooth or gum disease)
  • History of nephrolithiasis or cholelithiasis
  • Allergy to broccoli
  • Any chronic condition that compromises the participant as determined by medical history
  • Pregnancy
  • Inability to tolerate the study procedures
  • CF subjects: Infected with B. cepacia
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01315665). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search